Quinagolide hydrochloride - CAS 94424-50-7
Catalog number: 94424-50-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C20H34ClN3O3S
Molecular Weight:
432.02
COA:
Inquire
Targets:
Dopamine Receptor
Description:
Quinagolide hydrochloride is a selective dopamine D2 receptor agonist, also is a prolactin inhibitor.
Purity:
>98%
Appearance:
white solid powder
Synonyms:
NORPROLAC, BRN 6074559; BRN6074559; BRN-6074559; CV205-502.
MSDS:
Inquire
InChIKey:
DVLKVIJLALMCBQ-MSSRUXLCSA-N
InChI:
InChI=1S/C20H33N3O3S.ClH/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24;/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3;1H/t16-,17+,19-;/m1./s1
Canonical SMILES:
CCCN1CC(CC2C1CC3=C(C2)C(=CC=C3)O)NS(=O)(=O)N(CC)CC.Cl
Current Developer:
Ferring Pharmaceuticals Inc.
1.In vivo inhibition followed by exogenous supplementation demonstrates galactopoietic effects of prolactin on mammary tissue and milk production in dairy cows.
Lollivier V;Lacasse P;Angulo Arizala J;Lamberton P;Wiart S;Portanguen J;Bruckmaier R;Boutinaud M J Dairy Sci. 2015 Dec;98(12):8775-87. doi: 10.3168/jds.2015-9853. Epub 2015 Sep 18.
It has been previously shown that the long-term inhibition of milking-induced prolactin (PRL) release by quinagolide (QN), a dopamine agonist, reduces milk yield in dairy cows. To further demonstrate that PRL is galactopoietic in cows, we performed a short-term experiment that used PRL injections to restore the release of PRL at milking in QN-treated cows. Nine Holstein cows were assigned to treatments during three 5-d periods in a 3×3 Latin square design: 1) QN: twice-daily i.m. injections of 1mg of QN; 2) QN-PRL: twice-daily i.m. injections of 1mg of QN and twice-daily (at milking time) i.v. injections of PRL (2µg/kg body weight); and 3) control: twice-daily injections of the vehicles. Mammary epithelial cells (MEC) were purified from milk so that their viability could be assessed, and mammary biopsies were harvested for immunohistological analyses of cell proliferation using PCNA and STAT5 staining. In both milk-purified MEC and mammary tissue, the mRNA levels of milk proteins and BAX were determined using real-time reverse-transcription PCR. Daily QN injections reduced milking-induced PRL release. The area under the PRL curve was similar in the control and PRL injection treatments, but the shape was different.
2.Ca(2+)-dependent protein kinase C isoforms in rat pituitary hyperplasia: effect of in vivo treatment with quinagolide.
Lévy L;Alvaro V;Dubray C;Joubert D Eur J Pharmacol. 1994 Aug 16;268(3):327-34.
Ca(2+)-dependent protein kinase C (PKC) activity, diacylglycerol levels and PKC alpha, beta I, beta II and gamma expression were analyzed in the pituitary of female rats treated with estradiol alone (2 months) or in combination with quinagolide in the second month. Polymerase chain reaction (PCR) and Western blot analysis revealed the presence of PKC alpha, beta I and beta II isoenzymes in the rat pituitary gland but not of PKC gamma isoenzymes. Increases in pituitary weight and plasma prolactin levels induced by estradiol were associated with an increase in diacylglycerol pituitary content (1.55 +/- 0.06 versus 1.12 +/- 0.17 nmol diacylglycerol/mg protein in controls, P < 0.01). Cotreatment with quinagolide reversed these effects. Changes in PKC activity were accompanied by parallel changes in PKC alpha and beta I expressions. Estradiol treatment increased the expression of these isoforms whereas cotreatment with quinagolide antagonized these effects. PKC beta II expression was not affected. In conclusion, Ca(2+)-dependent PKC activity and protein expression are increased in hyperplastic pituitary cells, suggesting the involvement of this class of PKCs in the rat pituitary cell proliferation and/or hormonal secretion.
3.Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
Adler I;Barsi P;Czirják S;Varga I;Gergics P;Jakab C;Rácz K Gynecol Endocrinol. 2005 Jun;20(6):317-21.
We report the case of a macroprolactinoma in a 32-year-old woman, who presented with secondary amenorrhea, galactorrhea, increased plasma prolactin level (3259 ng/ml), headache and bi-temporal visual field defect. Magnetic resonance imaging showed a large pituitary tumor. The patient responded well to bromocriptine (7.5 mg/day) with improvement of clinical symptoms and normalization of plasma prolactin within a few weeks. After 4 months of treatment, tumor size was also reduced markedly. During continued treatment at the same dose of bromocriptine the plasma prolactin level remained normal, but after 8 months of treatment the patient suddenly complained of worsening of her visual fields, and magnetic resonance imaging indicated re-enlargement of the tumor. Bromocriptine was discontinued and transsphenoidal pituitary surgery was performed. After surgery the visual field defect improved, but postoperative plasma prolactin level (1104 ng/ml) and magnetic resonance imaging indicated a residual tumor. Postoperative treatment with quinagolide (0.15 mg/day) resulted in disappearance of all clinical symptoms, normalization of prolactin level and a reduction in size of the residual tumor. This case demonstrates that a dissociation of the inhibitory effect of bromocriptine on tumor size and prolactin level may rarely develop during the course of drug treatment in a patient with macroprolactinoma.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Dopamine Receptor Products


CAS 1257326-24-1 GSK 789472 hydrochloride

GSK 789472 hydrochloride
(CAS: 1257326-24-1)

GSK 789472 hydrochloride is a selective dopamine D3 receptor antagonist and D2 partial agonist (pEC50 values are <5.5 and 8.3, respectively). GSK 789472 exhibit...

CAS 234757-41-6 U 99194 maleate

U 99194 maleate
(CAS: 234757-41-6)

U 99194 maleate is a potent and selective dopamine D3 antagonist (Ki = 160, 2281 and > 10000 nM for human cloned D3, D2 and D4 receptors, respectively).

CAS 269718-84-5 Pardoprunox

Pardoprunox
(CAS: 269718-84-5)

Pardoprunox, also called as SLV308 or DU-126891, is a D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A rec...

CAS 58349-17-0 (S)-(-)-5-Methoxy-2-Aminotetraline hydrochloride

(S)-(-)-5-Methoxy-2-Aminotetraline hydro
(CAS: 58349-17-0)

(S)-(-)-5-Methoxy-2-Aminotetraline hydrochloride is a dopamine receptor agonist as a therapy for Parkinson’s disease.

CAS 94424-50-7 Quinagolide hydrochloride

Quinagolide hydrochloride
(CAS: 94424-50-7)

Quinagolide hydrochloride is a selective dopamine D2 receptor agonist, also is a prolactin inhibitor.

CAS 19262-68-1 Dexmethylphenidate HCl

Dexmethylphenidate HCl
(CAS: 19262-68-1)

Dexmethylphenidate HCl, a synthetic sympathomimetic controlled amine with CNS stimulating properties used most commonly in the treatment of attention-deficit di...

CAS 66104-23-2 Pergolide Mesylate

Pergolide Mesylate
(CAS: 66104-23-2)

Pergolide Mesylate is an antiparkinsonian agent which functions as a dopaminergic agonist.

CAS 84225-95-6 Raclopride

Raclopride
(CAS: 84225-95-6)

Raclopride, also known as FLA 870, is a selective and potent dopamine D2/D3 receptor antagonist. It has high affinity (Kd = 1.2 nM) and high selectivity for D2 ...

Chemical Structure

CAS 94424-50-7 Quinagolide hydrochloride

Quick Inquiry

Verification code

Featured Items